Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Invitae Corporation NVTA NYSE

NYSE • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
38/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$9.75
+51215.8%

Invitae Corporation (NVTA) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $0.02. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is NVTA = $10 (+51215.8% upside).

Financials: revenue is $516M, +35.3%/yr average growth. Net income is $3.1B (loss), growing at -277.8%/yr. Net profit margin is -601.6% (negative). Gross margin is 19.2% (-26.3 pp trend).

Balance sheet: total debt is $1.8B against $102M equity (Debt-to-Equity (D/E) ratio 17.19, leveraged). Current ratio is 6.41 (strong liquidity). Debt-to-assets is 89.6%. Total assets: $2.0B.

Analyst outlook: 4 / 15 analysts rate NVTA as buy (27%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 15/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).

$9.75
▲ 51215.79% Upside
Average Price Target
Based on 15 Wall Street analysts offering 12-month price targets for Invitae Corporation, the average price target is $9.75, with a high forecast of $17.00, and a low forecast of $2.25.
Highest Price Target
$17.00
Average Price Target
$9.75
Lowest Price Target
$2.25

NVTA SharesGrow Score Overview

45/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 15/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NVTA

✓
VALUE Pass
100/100
NVTA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $10, implying +52531.6% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
NVTA: +35.3%/yr revenue is, -277.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet NVTA: Debt-to-Equity (D/E) ratio 17.19 (leveraged), Current ratio is 6.41 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
15/100
NVTA: Gross margin is 19.2% (-26.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 15/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 4 / 15 analysts rate NVTA as buy (27%). Analyst consensus target is $10 (+52531.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
NVTA: Net profit margin is -601.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.015-2.34
Volume22.46M
Avg Volume (30D)12.7M
Market Cap$5.44M
Beta (1Y)1.59
Share Statistics
EPS (TTM)-13.18
Shares Outstanding$235.68M
IPO Date2015-02-12
Employees1,700
CEOKenneth D. Knight
Financial Highlights & Ratios
Revenue (TTM)$516.3M
Gross Profit$99.05M
EBITDA$-3.12B
Net Income$-3.11B
Operating Income$-714.24M
Total Cash$547.1M
Total Debt$1.75B
Net Debt$1.49B
Total Assets$1.95B
Price / Earnings (P/E)-0
Price / Sales (P/S)0.01
Analyst Forecast
1Y Price Target$10.00
Target High$17.00
Target Low$2.25
Upside+52,531.6%
Rating ConsensusHold
Analysts Covering15
Buy 27% Hold 40% Sell 33%
Company Info
CountryUS
ExchangeNYSE
CurrencyUSD
ISINUS46185L1035

Price Chart

Track all markets on TradingView
NVTA
Invitae Corporation ↗  ·  NYSE
Healthcare • Medical - Diagnostics & Research
0.02 52WK RANGE 2.34

People Also View

CRSP
CRSP
CRISPR Therapeutics AG
$56.86
+3.70%
 TWST
TWST
Twist Bioscience Corporation
$57.41
+13.95%
 NTLA
NTLA
Intellia Therapeutics, Inc.
$14.78
+3.65%
 PACB
PACB
Pacific Biosciences of California, Inc.
$1.57
+8.21%
 EDIT
EDIT
Editas Medicine, Inc.
$3.39
+5.94%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message